Oramorph (Morphine Sulfate)

Oramorph is an opioid analgesic that acts within the central nervous system to relieve pain.

• Acute postoperative pain: provides effective relief following surgical procedures.
• Cancer‑related pain: helps manage moderate to severe pain associated with malignant disease.
• Chronic non‑cancer pain: used when long‑term opioid therapy is deemed appropriate by a clinician.
• Severe traumatic injury pain: reduces pain intensity after major injuries.
• Palliative care pain: improves comfort in end‑of‑life settings.

• Morphine sulfate binds to μ‑opioid receptors in the brain, spinal cord and peripheral nervous system, mimicking endogenous opioids. This activation inhibits the release of excitatory neurotransmitters, reduces neuronal excitability, and diminishes the perception of pain signals, producing analgesia.

Side effects vary with dose, duration of therapy and individual sensitivity.

Common Side Effects

• Constipation: reduced gastrointestinal motility.
• Nausea and vomiting: stimulation of the chemoreceptor trigger zone.
• Drowsiness: central nervous system depression.
• Dry mouth: decreased salivary secretion.
• Sweating: autonomic activation.
• Itching: histamine release.

Serious or Rare Side Effects

• Respiratory depression: slowed breathing that can be life‑threatening.
• Severe hypotension: marked drop in blood pressure.
• Opioid dependence or withdrawal syndrome.
• Adrenal insufficiency: impaired cortisol production.
• Severe allergic reaction: anaphylaxis or angioedema.
• Neurotoxicity: seizures or altered mental status.

When prescribing Oramorph, clinicians should consider patient‑specific factors and follow safe‑use guidelines.

• Assess pain severity and prior opioid exposure: ensure opioid therapy is appropriate.
• Evaluate respiratory function: monitor for depression, especially in opioid‑naïve patients.
• Review concomitant CNS depressants: adjust dose or increase monitoring.
• Screen for substance‑use disorder: consider risk‑mitigation strategies.
• Adjust dose in renal or hepatic impairment: use the lowest effective dose.
• Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Morphine sulfate may interact with several medication classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Benzodiazepines: combined CNS depression can cause profound respiratory depression.
• Barbiturates: additive sedative effects increase risk of fatal overdose.
• Monoamine oxidase inhibitors (MAOIs): may precipitate severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Anticholinergics: may worsen constipation.
• Diuretics: can enhance hypotensive effects.
• Certain antidepressants (e.g., SSRIs, SNRIs): may increase risk of serotonin syndrome.
• CYP3A4 inhibitors (e.g., ketoconazole): may raise morphine plasma levels.
• CYP3A4 inducers (e.g., rifampicin): may reduce morphine effectiveness.